Comparing the Protection of Heterologous Booster of Inhaled Ad5-nCoV Vaccine and Hybrid Immunity Against Omicron BA.5 Infection: a Cohort Study of Hospital Staff in China

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Dec 19

PMID 39695978

Authors

Kai Wang

Ting Zeng

Zihao Guo

Jing Liang

Shengzhi Sun

Yongkang Ni

Chunyan Yan

Liang Yin

Lan Wang

Hui Li

Kailu Wang

Marc K C Chong

Naijun Tang

Jianghong Dai

Zhaohui Luo

Shi Zhao

Affiliations

Soon will be listed here.

Abstract

Background: After the exit "zero-COVID" strategy in mainland China by the end of 2022, a large-scale COVID-19 outbreak seeded by Omicron variants occurred. An inhaled adenovirus type-5 vector-based (i.e., inhaled Ad5-nCoV) COVID-19 vaccine was licensed earlier in 2021. In this study, we aimed to assess the real-world effectiveness of a heterologous booster of inhaled Ad5-nCoV vaccine against Omicron infection and compared with the protection from hybrid immunity (i.e., prior breakthrough infection).

Methods: In this retrospective cohort study, we identified 1087 out of a total of 1146 hospital staff from a tertiary hospital in Urumqi city, China from November 22 to December 29, 2022. Demographic characteristics, baseline health status, occupation, behavioral factors, laboratory test of serological IgG antibody, and timeline from immunization to laboratory-testing outcome were obtained. We analysed the individual-level vaccination status of inhaled Ad5-nCoV vaccine, prior SARS-CoV-2 infection status and baseline vaccination status, and other risk factors before follow-up. The protective effects of the heterologous inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection and hospitalization were calculated as relative rate reduction (RRR), which was estimated using multivariate Poisson regression models.

Results: A total of 1087 hospital staff (median age of 34 years, and 343 males [31.6%]), including 931 accepted for serological antibody tests, were recruited to assess the vaccine effectiveness (VE) of the inhaled Ad5-nCoV booster and hybrid immunity. Among the 1087 participants, 413 had a history of prior SARS-CoV-2 infection (before follow-up) but did not receive an inhaled Ad5-nCoV booster, and 674 reported no prior infection, including 390 who received an inhaled Ad5-nCoV booster. The highest serological IgG antibody level was detected among the inhaled Ad5-nCoV group, with a median of 294.59 S/CO, followed by the hybrid immunity group, with a median of 93.65 S/CO compared to the reference level of the inactivated vaccine group (most of whom received the Sinopharm/BBIBP-CorV vaccine). The inhaled Ad5-nCoV booster and hybrid immunity yielded RRRs of 41.9% (95% CI: 24.8, 55.0) and 97.9% (95% CI: 94.2, 99.2), respectively, against Omicron BA.5 infection, regardless of symptom status.

Conclusion: We found that hybrid immunity could provide a high level of protection against Omicron infection, while a heterologous inhaled Ad5-nCoV booster conferred a moderate level of protection. Our findings supported the rollout of a heterologous vaccination strategy regardless of preexisting vaccine coverage.

References

Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn H, Selvaraj M . Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022; 185(14):2422-2433.e13. PMC: 9181312. DOI: 10.1016/j.cell.2022.06.005. View

Chavda V, Vora L, Apostolopoulos V . Inhalable Vaccines: Can They Help Control Pandemics?. Vaccines (Basel). 2022; 10(8). PMC: 9413847. DOI: 10.3390/vaccines10081309. View

Sapkota B, Saud B, Shrestha R, Al-Fahad D, Sah R, Shrestha S . Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med. 2021; 29(3). PMC: 8754745. DOI: 10.1093/jtm/taab191. View

Zeng T, Lu Y, Zhao Y, Guo Z, Sun S, Teng Z . Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Respir Res. 2023; 24(1):246. PMC: 10571409. DOI: 10.1186/s12931-023-02542-y. View

Epsi N, Richard S, Lindholm D, Mende K, Ganesan A, Huprikar N . Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clin Infect Dis. 2022; 76(3):e439-e449. PMC: 9213853. DOI: 10.1093/cid/ciac392. View

Rodda L, Morawski P, Pruner K, Fahning M, Howard C, Franko N . Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022; 185(9):1588-1601.e14. PMC: 8926873. DOI: 10.1016/j.cell.2022.03.018. View

Ranzani O, Hitchings M, Melo R, de Franca G, Fernandes C, Lind M . Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun. 2022; 13(1):5536. PMC: 9537178. DOI: 10.1038/s41467-022-33169-0. View

Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View

Mudgal R, Nehul S, Tomar S . Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccin Immunother. 2020; 16(12):2921-2931. PMC: 7544966. DOI: 10.1080/21645515.2020.1805992. View

10.

Li J, Wu S, Guo X, Tang R, Huang B, Chen X . Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respir Med. 2022; 10(8):739-748. PMC: 9122540. DOI: 10.1016/S2213-2600(22)00087-X. View

11.

Yang J, Zheng W, Shi H, Yan X, Dong K, You Q . Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Med. 2021; 19(1):45. PMC: 7872877. DOI: 10.1186/s12916-021-01923-8. View

12.

Swarnalekha N, Schreiner D, Litzler L, Iftikhar S, Kirchmeier D, Kunzli M . T resident helper cells promote humoral responses in the lung. Sci Immunol. 2021; 6(55). PMC: 8063390. DOI: 10.1126/sciimmunol.abb6808. View

13.

Pilishvili T, Gierke R, Fleming-Dutra K, Farrar J, Mohr N, Talan D . Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. N Engl J Med. 2021; 385(25):e90. PMC: 8482809. DOI: 10.1056/NEJMoa2106599. View

14.

Langel S, Johnson S, Martinez C, Tedjakusuma S, Peinovich N, Dora E . Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med. 2022; 14(658):eabn6868. PMC: 9097881. DOI: 10.1126/scitranslmed.abn6868. View

15.

Li J, Hou L, Gou J, Yin Z, Wu S, Wang F . Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. Lancet Infect Dis. 2023; 23(10):1143-1152. DOI: 10.1016/S1473-3099(23)00350-X. View

16.

Gao J . Vaccination with CanSinoBIO's inhaled COVID-19 vaccine has begun in China. J Biosaf Biosecur. 2023; 4(2):163. PMC: 9791787. DOI: 10.1016/j.jobb.2022.12.002. View

17.

Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J . SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine. JAMA Netw Open. 2021; 4(8):e2119741. PMC: 8346938. DOI: 10.1001/jamanetworkopen.2021.19741. View

18.

Dhama K, Dhawan M, Tiwari R, Emran T, Mitra S, Rabaan A . COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022; 18(5):2045853. PMC: 8935456. DOI: 10.1080/21645515.2022.2045853. View

19.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

20.

Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N . Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med. 2022; 20(1):400. PMC: 9583051. DOI: 10.1186/s12916-022-02606-8. View